Rigel Pharmaceuticals, Inc. Q1 2026 Earnings Recap

Shares fell 6.6% after earnings as investors reacted negatively to the persistent first-quarter reimbursement challenges and seasonally impacted sales, signaling caution despite management's maintained full-year guidance.

Key Takeaways

• Q1 2026 net product sales reached $54.9 million, up 26% year-over-year but pressured by typical seasonal reimbursement dynamics affecting January and February volumes.
• TAVALISSE sales grew 31% year-over-year to $37.3 million, aided by both stronger demand and improved gross-to-net adjustments.
• GAVRETO sales increased 7% to $9.6 million, establishing itself as a stable portfolio contributor.
• REZLIDHIA generated $8 million in net product sales, continuing growth momentum.
• Management reiterated 2026 revenue guidance of $275 million to $290 million and forecasted net income profitability, though near-term demand headwinds weighed on investor sentiment.